|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Bejar, R, Stevenson, KE, Caughey, B, Lindsley, RC, Mar, BG, Stojanov, P, Getz, G, Steensma, DP, Ritz, J, Soiffer, R, Antin, JH, Alyea, E, Armand, P, Ho, V, Koreth, J, Neuberg, D, Cutler, CS, Ebert, BL|
|Journal||Journal of clinical oncology : official journal of the American Society of Clinical Oncology|
Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers and powerfully associated with clinical phenotype and prognosis. Whether these types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with MDS is not known.